Gilead Sciences shares rise 1.45% intraday after announcing AI-enabled manufacturing hub and HIV drug partnerships.

Gilead Sciences, Inc. rose 1.45% in intraday trading, with the company announcing a partnership with the U.S. State Department and PEPFAR to deliver lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for HIV prevention. Additionally, Gilead broke ground on a new AI-enabled manufacturing hub in the Bay Area, which will serve as an innovation and collaboration center for its technical development and manufacturing teams.